Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

February 9, 2023

Consolidated Financial Results
for the Nine Months Ended December 31, 2022
(Under Japanese GAAP)
Company name:
Listing:
Securities code:
URL:
Representative:
Inquiries:

Takara Bio Inc.
Tokyo Stock Exchange4974
https://www.takara-bio.co.jp
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in charge of PR & IR Department

Telephone:+81-77-565-6970
Scheduled date to file quarterly securities report:
February 10, 2023
Scheduled date to commence dividend payments:
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing:
No(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2022 (from April 1, 2022 to December
31, 2022)(1) Consolidated operating results (cumulative)
Net sales
Nine months ended(Percentages indicate year-on-year changes.)

Operating profit

Net income attributableto owners of the parent

Ordinary profit

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

Dec. 31, 2022

60,20631.9

19,403(2.6)

19,480(3.3)

14,595

1.6

Dec. 31, 2021

45,65954.5

19,926

126.7

20,154126.0

14,364150.8

Note: Comprehensive income

For the nine months ended Dec. 31, 2022:
For the nine months ended Dec. 31, 2021:
Fully diluted net income
per share

Net income per share
Nine months ended¥22,620 million; 32.4%¥17,080 million; 245.7%

Yen

Yen

Dec. 31, 2022

121.21

Dec. 31, 2021

119.29-(2) Consolidated financial position
Total assets
As of

Net assets

Equity-to-asset ratio

Net assets per share

Millions of yen

Millions of yen%

yen

Dec. 31, 2022

128,140

114,71189.3

950.45Mar. 31, 2022

115,71296,06482.9

796.18Reference:

EquityAs of Dec. 31, 2022:
As of Mar. 31, 2022:¥114,448 million¥95,873 million

2. Cash dividends
Annual dividends per shareFirst quarter-end

Second quarter-end

Third quarter-end

Yen

Yen

Yen

Yen

Yen

-

0.00

-

33.00

33.00

-

0.00

42.00

42.00

Fiscal year ended
Mar. 31, 2022
Fiscal year ending
Mar. 31, 2023

Fiscal year-end

Fiscal year ending
Mar. 31, 2023
(Forecast)

Total

Note: Revisions to the forecast of cash dividends most recently announced: Yes

3. Consolidated financial forecasts for the fiscal year ending March 31, 2023 (April. 1, 2022 – March. 31, 2023)(Percentages indicate year-on-year changes.)

Net sales
Millions of yen

Full year
Note:*

78.700Operating profit%

Millions ofyen%

20,000 (30.8)

20,100(29.4)% Millions of yen

16.2

Net income
attributable toowners of the parent

Ordinary profit

Millions ofyen

Net income per
share

%

Yen

14,500 (27.0)

120.42

Revisions to the financial forecast since the most recent announced: Yes

Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change
in scope of consolidation): None
Newly included: - companies (Company name)
Excluded:- companies (Company name)(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements:
None(3) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(4) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of Dec. 31, 2022

120,415,600 shares

As of Mar. 31, 2022

120,415,600 shares(ii) Number of treasury shares at the end of the period
As of Dec. 31, 2022-

shares

As of Mar. 31, 2022-

shares(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal
year)
Nine months ended Dec. 31, 2022

120,415,600 shares

Nine months ended Dec. 31, 2021

120,415,600 shares* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants oran audit corporation.
* Proper use of financial forecasts, and other special matters(Special note regarding forward-looking statements)
The forward-looking statements, including financial forecasts, contained in this document are determined by the Takara

Bio Inc. (the “Company”) based on information currently available to the Company and include a number of
uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For
information regarding the above, please refer to “1. Overview of Financial Results for the nine months ended December
31, 2022 (4) Future Outlook on page 2 of the attached document.

Contents of the attached document
1. Overview of Financial Results for the Nine Months ended December 31, 2022.....................................................................
(1) Overview of Financial Results............................................................................................................................. ...............
(2) Overview of Financial Position............................................................................................................................. ..............
(3) Overview of Cash Flows…………………………………………………………….…………………………….……...
(4) Future Outlook............................................................................................................................. .......................................
2. Consolidated Quarterly Financial Statements and Primary Notes...........................................................................................
(1) Consolidated Quarterly Balance Sheets............................................................................................................................. .
(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income..................................................................
(Consolidated Quarterly Statements of Profit or Loss)(Nine Months ended December 31, 2022).................................................................................................................
(Consolidated Quarterly Statements of Comprehensive Income)(Nine Months ended December 31, 2022).................................................................................................................
(3) Consolidated Quarterly Statements of Cash Flows.............................................................................................................
(4) Notes to Consolidated Quarterly Financial Statements.......................................................................................................
(Notes on Premise of Going Concern)..............................................................................................................................
(Notes in case of Changes in Marked Amount of Shareholders’ Equity).........................................................................
(Additional Information)............................................................................................................................. ......................
3. Supplementary Information............................................................................................................................. .........................
(1) Trends in Key Indicators for Business Management...........................................................................................................
(2) Comparative Consolidated Statement of Income................................................................................................................
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts.............................................................

-1-

2
2
2
2
3
4
4
6
6
7
8
9
9
9
9
10
10
11
12

1. Overview of Financial Results for the Nine Months ended December 31, 2022
(1) Overview of Financial Results
The outlook for the global economy in the fiscal year under review is uncertain due to the impact of the new Coronavirus disease(COVID-19), the prolonged trade friction between the U.S. and China, and Russia’s invasion of Ukraine.
Under these circumstances, Takara Bio Group is promoting initiatives to advance the development of fundamental biologics
development technologies and become a biologics development company that continuously creates new modalities through Reagentsand Instruments and CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal 2026, and thethree-year Medium-Term Management Plan FY2023, which ends in fiscal 20231. In addition, the Group worked aggressively to ensurea stable supply of testing-related products for the new Coronavirus and to establish a manufacturing system for regenerative medicine
and other products.
In the fiscal year under review, although sales of CDMO decreased year on year, sales of Reagents, Instruments, and Gene Therapy
increased year on year. In particular, Reagents for general research increased, while Reagents related to the new Coronavirus test
increased due to the impact of the spread of domestic infectious disease. As a result, net sales increased to ¥60,206 million (up 31.9%
year on year). Even though cost of sales increased to ¥23,771 million (up 105.7% year on year) due to changes in the sales mix, grossprofit increased to ¥36,434 million (up 6.8% year on year). Selling, general and administrative (SG&A) expenses were ¥17,031
million (up 20.2% year on year), mainly due to an increase in R&D expenses. Operating profit was ¥19,403 million (down 2.6% year
on year).
As a result of the decrease in operating profit, ordinary profit decreased to ¥19,480 million (down 3.3% year on year). Due to factors
including the recording of insurance income in extraordinary income, quarterly income before income taxes and others was ¥20,318
million (up 1.0% year on year), and net income attributable to owners of the parent was ¥14,595 million (up 1.6% year on year).
From the first quarter of the fiscal year under review, due to a review of management classifications, sales of reagents and otherproducts of GMP grade (for the manufacture of regenerative medicine products), which were previously included in Reagents, areincluded in Gene Therapy. As a result, net sales for the third quarter of the previous fiscal year have been reclassified based on the
new classification. In the third quarter of the previous fiscal year, ¥1,646 million, which was included in Reagents, has been
reclassified as Gene Therapy.
Since our group is a single segment, the disclosure by segment is omitted.
(2) Overview of Financial Position
Total assets at the end of the third quarter under review were ¥128,140 million, it was an increase of ¥12,427 million from the end of
the previous fiscal year. This was mainly due to increases of ¥10,739 million in note and accounts receivable-trade, ¥7,351 in cash
and deposits, and ¥3,260 million in property, plant and equipment mainly owing to the acquisition of our manufacturing facilities,
despite a decrease of ¥9,833 million in merchandise and finished goods.
Total liabilities at the end of the third quarter under review were ¥13,428 million, it was a decrease of ¥6,219 million from the endof the previous fiscal year. This was mainly due to decreases of ¥4,667 million in accrued income taxes and ¥1,383 million in othercurrent liabilities.
Total net assets at the end of the third quarter under review were ¥114,711 million, an increase of ¥18,646 million from the end of
the previous fiscal year. This was mainly due to increases of ¥10,621 million in retained earnings and ¥7,921 million in foreign
currency translation adjustment due to the yen’s depreciation.
(3) Overview of Cash FlowsNet cash provided by operating activities amounted to ¥13,261 million, a decrease of ¥2,139 million from the previous fiscal year.
This was mainly due to balance between cash inflow from profit before income taxes and others of ¥20,318 million, decrease ininventories of ¥9,929 million, depreciation and amortization of ¥2,976 million, and cash outflow from trade receivables-trade of
9,846 million and income taxes paid of ¥9,641 million.
Net cash used in investing activities was ¥9,551 million, a decrease of ¥3,829 million from the same period of the previous fiscal
year. This was mainly due to payments into time deposits of ¥7,312 million, purchase of property, plant and equipment andintangible assets of ¥3,750 million, and proceeds from withdrawal of time deposits of ¥1,230 million.
Net cash used in financing activities amounted to ¥4,076 million, an increase of ¥2,041 million from the previous fiscal year,
mainly due to cash dividends paid of ¥3,967 million.
As a result of the above, the balance of cash and cash equivalents at the end of the third quarter under review, including the effectof exchange rate changes on cash and cash equivalents, increased by ¥1,052 million from the end of the previous fiscal year to¥23,212 million

1

FY2026 and FY2023 refer to the fiscal year ending March 31, 2026 and 2023, respectively.

-2-(4) Future Outlook
The financial forecast and dividend forecast announced in the financial results summary for the six months ended September 30,
2022 on November 10, 2022 have been revised. For details, please refer to “Notice Concerning Revisions to the Financial Results
Forecasts and Dividend Forecasts (Dividend Increase)” announced today (February 9, 2023).
For comparison of the revised consolidated financial forecasts with previous fiscal year’s results and the previous financial
forecasts, please refer to the “Comparative Statement of Income Relating to Consolidated Financial Forecasts” on page 12.

-3-2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2022
AssetsCurrent asset
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net

Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets-4-

As of Dec. 31, 2022

23,633
17,845
18,966
1,361
3,738
2,637
(40)
68,141

30,98428,584
9,133
1,921
4,219
2,127
(61)
76,90923,553(5,937)
17,615
7,626(4,147)
3,479
9,530(5,516)
4,014
8,413
1,519
1,642
(287)
1,355
36,395

26,134(7,003)
19,131
8,354(4,859)3,495
10,453(6,377)
4,075
8,935
2,635
1,789
(407)
1,381
39,656

6,309
2,850
9,159

7,448
2,726
10,1752,015
2,015
47,571
115,712

1,399
1,399
51,231
128,140

(Millions of yen)
As of Mar. 31, 2022
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Shareholders’ equity
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Cumulative remeasurements of retirement
benefit
Total accumulated other comprehensive
incomeNon-controlling interests
Total net assets
Total liabilities and net assets-5-

As of Dec. 31, 2022

1,959
5,498
923
8,999
17,380

1,582
830
994
7,615
11,022

788
1,478
2,266
19,647

794
1,610
2,405
13,428

14,96532,89345,00992,868

14,96532,89355,630103,489

3,208

11,130

(204)

(171)

3,004

10,958191
96,064
115,712

262
114,711
128,140

(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(Nine Months ended December 31, 2022)(Millions of yen)

Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision of allowance
Other
Total SG&A expenses
Operating profit
Non-operating income
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating income
Non-operating expense
Interest expenses
Foreign exchange loss
Rent expenses on real estate
Other
Total non-operating expenses
Ordinary profit
Extraordinary gains
Gain on sale of fixed assets
Insurance received
National subsidies
Total extraordinary profit
Extraordinary losses
Loss of sales on non-current assets
Asset shrinkage losses
OthersTotal extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent

Nine months ended
Dec. 31, 2021
45,65911,55934,100Nine months ended
Dec. 31, 2022
60,206
23,77136,434

3,846
174
4,020
365
5,766
14,17419,926

4,382
188
5,867
408
6,184
17,031
19,403

91
45
101
59
297

98
113
39
252

17
43
7
68
20,154

18
106
48
1
175
19,480

0
3,205
3,205

250
652
902

40
3,205
3,245
20,114
5,640
56
5,696
14,41854
14,36425
39
64
20,318
4,857
827
5,684
14,63338
14,595-6-

(Consolidated Quarterly Statements of Comprehensive Income)(Nine Months ended December 31, 2022)(Millions of yen)
Nine months ended
Dec. 31, 2021
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest-7-

Nine months ended
Dec. 31, 2022

14,418

14,633

2,626
35
2,661
17,080

7,954
32
7,987
22,62017,01465

22,54970

(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)
Nine months ended
Dec. 31, 2021
Net cash provided by (used in) operating activities
Profit before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful
accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Insurance claim income
Loss (gain) on sale and retirement of fixed assets
Decrease (increase) in trade receivables-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payabletrade
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Proceeds from insurance income
Subsidies received
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Subsidies received
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period-8-

Nine months ended
Dec. 31, 2022

20,114
2,606
71
370

20,318
2,976
60
438

(7)

(5)

(31)
(5)
(91)
17
39
286
(1,322)

(39)
4
(98)
18
(652)
(225)
(9,846)
9,929

(972)

(766)

(861)
(29)
20,18693(17)(5,532)671
15,401(277)
355
22,18980(18)(9,641)
652
13,261(10,781)2,215(7,312)
1,230(8,732)(3,750)

3

394

(42)
3,960
(2)
(13,380)(121)
8(9,551)(1,923)(111)(2,034)(3,967)(108)(4,076)

640

1,418

626
23,30823,935

1,052
22,16023,212

(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No item to report.
(Additional Information)(Accounting Estimates for the Impact of the COVID-19)
No material changes have been made to the assumptions used in the previous fiscal year, including the future
spread and timing of convergence of the COVID-19.

-9-

3. Supplementary Information(1)Trends in Key Indicators for Business Management
1) Cash Flows
Nine months ended
Dec. 31, 2021
(Apr. 1, 2021 – Dec. 31, 2021)

Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities

15,401(13,380)(2,034)

Nine months ended
Dec. 31, 2022

(Millions of yen)
Year ended
Mar. 31, 2022

(Apr. 1, 2022 – Dec. 31, 2022) (Apr. 1, 2021 – Mar. 31, 2022)

13,261(9,551)(4,076)

6,985(7,071)(2,070)Nine months ended
Dec. 31, 2022

(Millions of yen)
Year ended
Mar. 31, 2022

2) Sales Breakdown by Region
Nine months ended
Dec. 31, 2021
(Apr. 1, 2021 – Dec. 31, 2021)

Japan
United States
China
Asia excluding Japan and China
EuropeOthersTotal

21,781
7,298
8,373
4,499
3,528
177
45,659- 10 -(Apr. 1, 2022 – Dec. 31, 2022) (Apr. 1, 2021 – Mar. 31, 2022)

35,931
9,879
7,950
2,589
3,660
195
60,206

34,076
10,186
11,908
6,614
4,668
244
67,699(2) Comparative Consolidated Statement of Income(Yen amounts are rounded down to millions, unless otherwise noted.)
Nine months ended
Nine months ended
Y/Y
Y/Y
Dec. 31, 2021
Dec. 31, 2022
changeratio(Net sales)
Reagents
35,351
52,46917,11748.4%
Instruments
1,040
1,080
40
3.9%
CDMO
7,474
4,669
(2,804)(37.5%)
Gene Therapy
1,793
1,985
192
10.7%
Total net sales
45,65960,206
14,546
31.9%(Operating profit and Loss)
45,65960,206
14,546
31.9%
Net sales
Cost of sales
11,55923,771
12,212105.7%
Gross profit
34,10036,4342,334
6.8%
SG & A expenses
14,174
17,0312,856
20.2%
Transportation expenses
615
506
(109)
(17.7%)
Advertising expenses
43
33
(9)
(22.4%)
Promotion expenses
475
506
30
6.4%
R&D expenses
4,020
5,867
1,846
45.9%
8,631
9,735
1,103
12.8%
Administrative expense, other
Enterprise taxes (external
standards taxation)

Operating profit(Non-operating income andExpenses)Non-operating income
Non-operating expenses
Ordinary profit

386

381

(5)

(1.4%)

19,926

19,403(522)(2.6%)

297
68
20,154252
175
19,480

(45)
106
(674)

(15.2%)
155.2%(3.3%)

3,205
3,245

902
64

(2,303)(3,181)(71.8%)(98.0%)

20,114

20,318

203

1.0%

5,696
14,418

5,684
14,633(11)215(0.2%)
1.5%

54

38

(16)

(29.6%)

14,364

14,595

231

1.6%

2,606

2,976

370

14.2%

370

438

67

18.2%

(Extraordinary income & Losses)

Extraordinary income
Extraordinary losses
Income before income
taxes and others
Income taxes
Net income
Net income (loss) attributable tonon-controlling interests

Net income attributableto owners of the parent
Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in"Gene Therapy " since the year ending March 31, 2023. The result for the year ended Mar. 31, 2022 in this table have been
reclassified to reflect these changes.

- 11 -

(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts(Yen amounts are rounded down to millions, unless otherwise noted.)Year
Year ending
ended
Previous Previous
Mar. 31, 2023
Y/Y
Y/Y
Mar. 31,
forecast
forecast
ChangeRatio
Previous Current
2022
ChangeRatio
forecast
forecast
Actual(Net sales)
Reagents
52,47965,106
66,275
13,795
26.3%
1,169
1.8%
Instruments
1,518
1,716
1,550
31
2.1%
(165)
(9.7%)
CDMO
11,426
8,356
8,242(3,184)(27.9%)(113)(1.4%)
Gene Therapy
2,275
2,621
2,631
356
15.7%
10
0.4%
Total Net Sales
67,69977,80078,70011,000
16.2%
900
1.2%
(Operating profit and Loss)
67,69977,80078,70011,000
16.2%
900
1.2%
Net sales
Cost of sales
18,48834,06833,64215,15482.0%(426)(1.3%)
Gross profit
49,21143,73145,057(4,154)(8.4%)
1,326
3.0%
SG & A expenses
20,30924,731
25,057
4,747
23.4%
326
1.3%
Transportation expenses
755
667
680
(74)
(9.9%)
13
2.0%
Advertising expenses
58
51
48
(9)
(16.0%)(2)(4.8%)
Promotion expenses
683
729
747
63
9.3%
17
2.4%
R&D expenses
6,109
8,713
8,654
2,544
41.7%
(59)
(0.7%)
Administrative expenses,
12,153
14,11814,445
2,292
18.9%
327
2.3%
other
Enterprise taxes(external standards
548
450
479
(68)
(12.5%)
29
6.5%
taxation)
28,902
19,00020,000(8,902)(30.8%)
1,000
5.3%
Operating profit(Non-operating income andExpenses)Non-operating income
357
244
320
(37)
(10.5%)
75
31.0%
Non-operating expenses
800
144
220
(580)
(72.5%)
75
52.4%
28,45919,10020,100(8,359)(29.4%)
1,000
5.2%
Ordinary profit(Extraordinary gains &Losses)Extraordinary gains
4,476
902
914
(3,561)(79.6%)
12
1.3%
Extraordinary losses
5,403
75
274
(5,129)(94.9%)
199
265.5%
Income before income
27,532
19,927
20,739(6,792)(24.7%)
812
4.1%
taxes and others
Income taxes
7,624
6,102
6,203
(1,420)(18.6%)
101
1.7%
Net income
19,90813,825
14,536(5,371)(27.0%)
711
5.1%
Net income (loss)
attributable to non58
25
36
(22)
(37.9%)
1144.0%
controlling interests
Net income attributable
19,84913,80014,500(5,349)(27.0%)
700
5.1%
to owners of parent
Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill

3,554

4,207

4,068

513

14.4%

(138)

(3.3%)

500

599

599

98

19.8%

(0)

(0.1%)※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in "Gene
Therapy " since the year ending March 31, 2023. The results for the year ended Mar. 31, 2022 in this table have been reclassified toreflect these changes.

- 12 -